Survival in patients initiating home parenteral support due to nonmalignant short bowel syndrome compared with background population
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Survival in patients initiating home parenteral support due to nonmalignant short bowel syndrome compared with background population. / Fuglsang, Kristian Asp; Brandt, Christopher Filtenborg; Jeppesen, Palle Bekker.
In: Clinical Nutrition ESPEN, Vol. 50, 2022, p. 170-177.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Survival in patients initiating home parenteral support due to nonmalignant short bowel syndrome compared with background population
AU - Fuglsang, Kristian Asp
AU - Brandt, Christopher Filtenborg
AU - Jeppesen, Palle Bekker
N1 - Publisher Copyright: © 2022 European Society for Clinical Nutrition and Metabolism
PY - 2022
Y1 - 2022
N2 - Background: Survival has frequently been studied and reported in patients with long term intestinal failure (IF). However, studies comparing the survival and mortality rates with the background population are rare. This study compares the survival in an adult IF, non-malignant, short bowel syndrome (SBS) cohort with a control group and with age- and sex-specific background mortality rates. Design: Patients with SBS, defined by a small bowel length of 200 cm or less, due to non-malignant disease, were included and followed until death or censoring on 31 December 2017. Causes of deaths occurring during home parenteral support (HPS) were assessed by review of the charts. Each case was matched with ten controls from the background population according to year of HPS initiation, age, and sex, and their survival was compared. Furthermore, age- and sex-specific mortality rates of the background population were used to calculate the standardized mortality ratio (SMR) and excess mortality. Results: After five years, patients who initiated HPS had a relative survival of 76%. The SMR was 5.0 and the excess mortality was 50 per 1000 years. HPS-related deaths were assessed to account for 11% of deaths during HPS and occurred with an incidence of 10 per 1000 years. The excess mortality was as low as 15 per 1000 years in cases aged less than 40 years. Patients weaning off HPS had a mortality rate closer to that expected in the background population. Conclusions: In adult patients with a non-malignant cause of SBS-IF, the excess mortality was 50 per 1000 years. However, HPS related deaths were rarely registered with an incidence of 10 HPS related deaths per 1000 HPS treatment years.
AB - Background: Survival has frequently been studied and reported in patients with long term intestinal failure (IF). However, studies comparing the survival and mortality rates with the background population are rare. This study compares the survival in an adult IF, non-malignant, short bowel syndrome (SBS) cohort with a control group and with age- and sex-specific background mortality rates. Design: Patients with SBS, defined by a small bowel length of 200 cm or less, due to non-malignant disease, were included and followed until death or censoring on 31 December 2017. Causes of deaths occurring during home parenteral support (HPS) were assessed by review of the charts. Each case was matched with ten controls from the background population according to year of HPS initiation, age, and sex, and their survival was compared. Furthermore, age- and sex-specific mortality rates of the background population were used to calculate the standardized mortality ratio (SMR) and excess mortality. Results: After five years, patients who initiated HPS had a relative survival of 76%. The SMR was 5.0 and the excess mortality was 50 per 1000 years. HPS-related deaths were assessed to account for 11% of deaths during HPS and occurred with an incidence of 10 per 1000 years. The excess mortality was as low as 15 per 1000 years in cases aged less than 40 years. Patients weaning off HPS had a mortality rate closer to that expected in the background population. Conclusions: In adult patients with a non-malignant cause of SBS-IF, the excess mortality was 50 per 1000 years. However, HPS related deaths were rarely registered with an incidence of 10 HPS related deaths per 1000 HPS treatment years.
KW - Home parenteral support
KW - Intestinal failure
KW - Short bowel syndrome
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85132520528&partnerID=8YFLogxK
U2 - 10.1016/j.clnesp.2022.05.023
DO - 10.1016/j.clnesp.2022.05.023
M3 - Journal article
C2 - 35871920
AN - SCOPUS:85132520528
VL - 50
SP - 170
EP - 177
JO - Clinical Nutrition ESPEN
JF - Clinical Nutrition ESPEN
SN - 2405-4577
ER -
ID: 325021220